Lovastatin lowers the risk of breast cancer: a population-based study using logistic regression with a random effects model

SpringerPlus

Table 1 Baseline variables included demographic characteristics and comorbid medical disorders for two cohorts (n = 25,992)

Baseline variable	Breast cancer patients n = 4332		Control patients n = 21,660		p value
Baseline variable	No	%	No	%	p value
Characteristics
Age (years)
18–30	68	1.6	340	1.6
31–40	428	9.9	2140	9.9
41–50	1402	32.4	7010	32.4
51–60	1306	30.1	6530	30.1
61–70	721	16.6	3605	16.6
>70	407	9.4	2035	9.4
Urbanization level					<0.001
Urban 1	1681	38.8	6857	31.7
Urban 2	1273	29.4	6348	29.3
Urban 3	566	13.1	3049	14.1
Urban 4	455	10.5	2994	13.8
Urban 5–7	357	8.2	2412	11.1
Comorbid medical disorders CCI
Myocardial infarction					0.206
Yes	24	0.6	158	0.7
No	4308	99.4	21,502	99.3
Congestive heart failure					0.179
Yes	269	6.2	1466	6.8
No	4063	93.8	20,194	93.2
Peripheral vascular disease					0.160
Yes	199	4.6	1108	5.1
No	4133	95.4	20,552	94.9
Cerebrovascular disease					0.191
Yes	447	10.3	2385	11.0
No	3885	89.7	19,275	89.0
Dementia					0.004
Yes	87	2.0	601	2.8
No	4245	98.0	21,059	97.2
Chronic pulmonary disease					0.009
Yes	1217	28.1	5665	26.2
No	3115	71.9	15,995	73.8
Connective tissue disease-rheumatic disease					0.587
Yes	323	7.5	1564	7.2
No	4009	92.5	20,096	92.8
Peptic ulcer disease					0.057
Yes	1470	33.9	7028	32.4
No	2862	66.1	14,632	67.6
Mild liver disease					<0.001
Yes	1240	28.6	4849	22.6
No	3092	71.4	16,762	77.4
Diabetes					0.065
Yes	945	21.8	4455	20.6
No	3387	78.2	17,205	79.4
Paraplegia/hemiplegia					0.420
Yes	99	2.3	543	2.5
No	4233	97.7	21,117	97.5
Renal disease					0.188
Yes	180	4.2	1002	4.6
No	4152	95.8	20,658	95.4
Moderate or severe liver disease					0.781
Yes	14	0.3	78	0.4
No	4318	99.7	21,582	99.6
Metastatic cancer					<0.001
Yes	339	7.8	94	0.4
No	3993	92.2	21,566	99.6
AIDS/HIV					1.000
Yes	0	0.0	2	0.0
No	4332	100.0	21,658	100.0
CCI score (SD)	1.63	(1.58)	1.48	(1.55)	<0.001
Medicine use
Statins					0.045
Yes	632	14.6	3422	15.8
No	3700	85.4	18,238	84.2